| Name | threonine-protein kinase B-raf | ||
| UniProt ID | BRAF_HUMAN | ||
| Gene Name | BRAF | ||
| Gene ID | 673 | ||
| Synonyms |
BRAF, B-RAF1, B-raf, BRAF-1, BRAF1, NS7, RAFB1
|
||
| Sequence |
MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEH
IEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLLESLGNGTDFSVSSSASMDTV TSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDS LKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRK TFFTLAFCDFCRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPI PQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQR DRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSP GPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDV AVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHH LHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATV KSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNIN NRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARS LPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGAFPVH |
||
| Pathway Map | MAP LINK | ||
| T.C. Number | 8.A.23.1.48 | ||
| KEGG ID | hsa673 | ||
| TTD ID | T63235 | ||
| Pfam | PF00069; PF00130; PF02196; PF03107; PF03109; PF06293; PF07714; PF08746; PF14531 | ||
| Pair Name | Withaferin A, Oxaliplatin | |||
| Phytochemical Name | Withaferin A | |||
| Anticancer drug Name | Oxaliplatin | |||
| Disease Info | [ICD-11: 2C10] | Pancreatic cancer | Investigative | |
| Regulate Info | Down-regulation | threonine-protein kinase B-raf | Phosphorylation | |
| Result | These results support the notion that combination treatment with oxaliplatin and WA could facilitate development of an effective strategy for PC treatment. | |||
| Pair Name | All-trans retinoic acid, Midostaurin | |||
| Phytochemical | All-trans-retinoic acid | |||
| Drug | Midostaurin | |||
| Disease Info | [ICD-11: 2A60.Z] | Acute myeloid leukemia | Investigative | |
| Regulate Info | Up-regulation | threonine-protein kinase B-raf | Expression | |
| Result | Combination of midostaurin and ATRA exerts dose-dependent dual effects on acute myeloid leukemia cells with wild type FLT3 | |||
| Pair Name | Sulforaphene, Photodynamic therapy | |||
| Phytochemical | Sulforaphene | |||
| Drug | Photodynamic therapy | |||
| Disease Info | [ICD-11: 2D10.Z] | Thyroid cancer | Investigative | |
| Regulate Info | Down-regulation | threonine-protein kinase B-raf | Phosphorylation | |
| Result | Our work designates sulforaphene as a unique natural enhancer of efficacy with PDT against anaplastic thyroid cancer. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Synergistic antitumor activity of withaferin A combined with oxaliplatin triggers reactive oxygen species-mediated inactivation of the PI3K/AKT pathway in human pancreatic cancer cells. Cancer Lett. 2015 Feb 1;357(1):219-230. doi: 10.1016/j.canlet.2014.11.026. | Click |
| 2 | Combination of midostaurin and ATRA exerts dose-dependent dual effects on acute myeloid leukemia cells with wild type FLT3. BMC Cancer. 2022 Jul 9;22(1):749. doi: 10.1186/s12885-022-09828-2. | Click |
| 3 | Sulforaphene Enhances The Efficacy of Photodynamic Therapy In Anaplastic Thyroid Cancer Through Ras/RAF/MEK/ERK Pathway Suppression. J Photochem Photobiol B. 2018 Feb;179:46-53. doi: 10.1016/j.jphotobiol.2017.12.013. | Click |
